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Abstract  
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 
(HHV8), is the infectious cause of three types of human cancer: Kaposi’s sarcoma, primary 
effusion lymphoma, and multicentric Castleman’s disease. To aid in viral replication, KSHV 
encodes a viral serine/threonine protein kinase (vPK), a protein that plays a role in the production 
of infectious KSHV virions. The vPK protein alters the phosphorylation of several cellular 
substrates, leading to the augmentation of protein synthesis and the multiplication of virally 
infected cells. While current research shows that vPK can mimic some cellular kinases to 
phosphorylate approximately ten different cellular substrates, there are likely more substrates for 
vPK than what is currently known. This project aimed to confirm two new phosphorylation 
substrates, nucleophosmin (NPM1) and human antigen R (HUR), which were identified by high-
throughput phosphoproteomics. Immunoblotting revealed overall protein levels of NPM1 and 
HUR did not change in the presence or absence of vPK.  Additionally, no apparent effect on the 
phosphorylation of NPM1 by vPK was observed. These results indicate that vPK may not be 
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affecting the phosphorylation of NPM1. Detection of HUR phosphorylation is still being 
optimized and it has yet to be determined whether HUR phosphorylation levels are affected in 
the presence of vPK. The identification of new phosphorylation substrates of vPK, such as 
NPM1 and HUR, has the potential for the development of new treatments for KSHV-related 
cancers by targeting vPK kinase activity. 
 
Introduction 
 Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 
(HHV8), is an oncovirus1. As a member of the herpesvirus family, KSHV causes lifelong 
infection in the host2. The virus infects endothelial cells, B cells, monocytes, dendritic cells, and 
epithelial cells1. KSHV is the infectious cause of three types of human cancer: Kaposi’s sarcoma 
(KS)3, primary effusion lymphoma4, and multicentric Castleman’s disease5. KS is the most 
common type of cancer in individuals with HIV/AIDS6. While KSHV is necessary for KS 
development, cofactors are required to activate KSHV out of dormancy and produce sarcoma1. 
The most common cofactor is HIV infection, but other causes of immunodeficiency serve as 
cofactors for KS development as well1.  
KSHV, like all herpesviruses, is an enveloped, double-stranded DNA virus with two 
different life cycles: latent and lytic2. During primary infection, KSHV encounters multiple 
components of the innate immune response which induce the virus to establish molecular 
latency1. During latency, the main goal of KSHV is survival2. The virus does not replicate during 
latency but induces the proliferation of infected cells to transfer the viral genome2. KSHV 
encodes several latent proteins that allow the virus to evade the host’s innate and adaptive 
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immune responses, induce cellular proliferation, prevent apoptosis, and change the cellular 
environment to establish and maintain latency7. 
The process of maintaining latency coincides with many of the hallmarks of cancer8. As 
the virus alters the cellular environment to maintain latency and survive in host cells, KSHV can 
lead to the formation of cancer7. 
During lytic replication, new virions are made and the virus is transmittable9. One of the 
proteins that the virus expresses during the lytic stage is a viral serine/threonine protein kinase 
(vPK), which is encoded by the ORF36 gene10. vPK plays a role in the production of KSHV 
virions to aid in the transmission of the virus11. As a kinase, vPK adds phosphate groups to 
cellular proteins through a process called phosphorylation10. Protein phosphorylation activates 
cellular pathways and alters protein interactions, making it an important process for cellular 
events such as signal transduction, cell growth, and protein synthesis12. vPK alters the 
phosphorylation of host proteins, leading to the activation of protein synthesis and the 
multiplication of virally infected cells13. Expression of vPK can also induce angiogenesis, which 
causes the formation of new blood vessels to supply KSHV-infected cancer cells with nutrients 
to survive13. 
Based on current research, vPK seems to be mimicking several cellular kinases. To aid in 
viral replication, vPK acts like cyclin-dependent kinase 2 (CDK2)14, one of the CDKs that plays 
a vital role in cell cycle regulation15. vPK also mimics the function of cellular S6 kinase B1 
(S6KB1), a protein with target substrates involved in protein synthesis, cellular proliferation, and 
vascularization13. vPK has the ability to bypass the regulation of upstream kinases in the S6 
pathway that would otherwise inhibit protein synthesis during viral infection to activate S612. In 
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addition to CDK2 and S6KB1 substrates, vPK phosphorylates several other cellular substrates 
including eukaryotic initiation factor 4E (eIF4E)12 and c-Jun N-terminal kinase (JNK)16.  
Our lab hypothesizes that there are still more vPK substrates than what is currently 
known. In order to characterize novel phosphorylation substrates of vPK, cells were collected by 
the Damania Lab and submitted to the Proteomics Core at the University of North Carolina at 
Chapel Hill. The following work uses immunoblotting and immunoprecipitation experiments in 
an attempt to confirm two of the phosphorylation substrates identified by high-throughput 
phosphoproteomics. For one of these substrates, no effect on phosphorylation was observed in 
the presence of vPK. It has yet to be determined whether phosphorylation levels of the second 
substrate are affected in the presence of vPK. The continuation of this project to study how vPK 
affects the activity of these proteins and others will allow for a greater understanding of how 
viral proteins alter the cellular environment, with the potential for the development of new 
treatments for KSHV-related cancers that target vPK kinase activity.  
 
Materials and Method 
Cell Culture. Cells from the malignant human B-cell line (BJAB), human embryonic kidney-
293T (HEK-293T) cells, and human umbilical vein endothelial cells (HUVECs) were used. 
BJAB cells were previously transduced by my postdoctoral mentor, Dr. Ariana Bravo Cruz, to 
stably express empty vector (EV) or vPK. These cells were grown in RPMI media supplemented 
with 10% fetal bovine serum (FBS), penicillin and streptomycin (100 U/μl), 2mM L-glutamine 
and maintained under geneticin selection (0.8 ml/ml). HEK-293T cells were grown in D-MEM 
media supplemented with 10% FBS, penicillin and streptomycin (100 U/μl), and 2mM L-
glutamine. HUVECs were previously transduced to stably express EV or vPK12 and were grown 
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in endothelial cell growth media with 10% FBS, as described above. Cells were kept in an 
incubator at 37⁰C with 5% CO2.  
 
Transfections. HEK-293T cells were plated in 6-well plates (5 x 105 cells per well) for 24 hours 
and then transfected using Lipofectamine 3000 Reagent with 2,000 µg of an EV or vector-
expressing v5-tagged vPK protein, previously generated by the Damania lab, for an additional 24 
hours.  
 
Cell conditioning. For serum starvation, transfected HEK-293T or transduced BJAB cells were 
incubated in fresh media with 10% FBS (normal conditions) or in media without FBS (starvation 
conditions) for 24 hours. To synchronize cells in G2/M phase, HUVECs were plated in 10 cm 
dishes with 10% FBS for 24 hours and then incubated in 5% FBS with 100 µg/mL InSolution™ 
Nocodazole (Sigma-Aldrich) for 16 hours. 
 
Immunoblots. BJAB EV and BJAB vPK-expressing cells were collected by centrifugation at 
1500 RPM for 3 minutes and the supernatant was removed. Cells were lysed using NP-40 buffer 
(1% NP-40, 50 mM Tris-HCl pH 8, 150 mM NaCl, protease inhibitor tablet, 30 mM beta-
glycerolphosphate, 50 mM NaF, 1 mM Na3VO4), then incubated on ice for 15 minutes. Lysates 
were centrifuged at 13,200 rpm for 10 minutes. While BJABs were grown in suspension, HEK-
293T cells and HUVECS are adherent cell lines and required different conditions for lysate 
collection. Lysates of HEK-293T cells and HUVECs were generated as described below. D-
MEM or endothelial cell growth media was aspirated from each well and cells were washed with 
ice-cold PBS. PBS was aspirated and cells were lysed with NP-40 buffer. Lysates were 
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transferred to Eppendorf tubes and incubated on ice for 15 minutes, then centrifuged at 13,200 
rpm for 10 minutes.  
Protein concentrations were calculated using the Bradford technique. Equal amounts of 
proteins were electrophoresed on 12.5% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), with the exception of an 8% SDS-PAGE gel used for the 
immunoblot in Figure 1A. Transfer onto nitrocellulose membrane followed. Membranes were 
blocked for 30 minutes at room temperature with milk or BSA depending on the manufacturer’s 
recommendations for the antibodies, then incubated overnight at 4°C with the appropriate 
primary antibody. The following primary antibodies were used: anti-vPK (1:500, generated by 
Genescript using a GST-tagged 1-150 amino acid vPK fragment); anti-v5-HRP (1:1000, 
Invitrogen, 46-0708);  anti-HUR (1:1000, Santa Cruz Biotechnology, sc-5261); anti-
nucleophosmin (1:2500, Abcam, ab10530); anti-phospho nucleophosmin (Thr234/237, 1:1000, 
Abcam, ab118637); anti-eIF4E (1:1660, Cell Signaling Technology, 2067S); anti-phospho eIF4E 
(1:1660, Cell Signaling Technology, 9741S); anti-tubulin (1:5000, Cell Signaling Technology, 
9099S); anti-phosphoserine CDK substrate (1:1000, Cell Signaling Technology, 9477S); anti-
phospho CDC2 (1:1000, Cell Signaling Technology, 9114S); anti-tubulin (1:5000, Cell 
Signaling Technology, 9099S); anti-mouse IgG HRP (1:1000, eBioscience E07429-1634).  
After washing with TBS-T to remove unbound antibodies, membranes were incubated 
with the appropriate HRP-conjugated secondary antibody for one hour at room temperature: anti-
mouse IgG (1: 2000, Cell Signaling Technology, 7076S) or anti-rabbit IgG (1:2000, Cell 
Signaling Technology, 7074S). Results were visualized with the Bio-Rad Clarity Western 
Blotting Detection System. Bands were visualized using chemiluminescence imaging.  
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Immunoprecipitations. HEK-293T cells, BJAB cells, and HUVECs lysates were collected as 
described above. Protein concentrations were calculated using the Bradford technique. For HUR 
and IgG immunoprecipitations, samples were prepared with 200µg of lysate, 1 µg of antibody, 
and various amounts of NP-40 buffer to bring the total volume of each sample to 1 mL. For vPK 
immunoprecipitations, samples were prepared with 200µg of lysate, 2.5 µg of antibody, and 
various amounts of NP-40 buffer to bring the total volume of the sample to 1 mL. Samples were 
incubated at 4°C for 2 hours. At 2 hours, 20 µL of Protein A/G PLUS-Agarose 
Immunoprecipitation Reagent (Santa Cruz Biotechnology, sc-2003) was added to each sample. 
Samples were then incubated at 4°C overnight. The following day, samples were centrifuged at 
8,000 rpm for 30 seconds. After centrifugation, the supernatant was aspirated and the pellet was 
washed with 1 mL of NP-40 buffer followed by centrifugation. Samples were washed for a total 
of 4 times and then boiled at 95°C for 10 minutes with 40 µL of laemmli sample buffer. Samples 
were centrifuged at 8,000 rpm once more following denaturation. Immunoblotting followed. 
 
Results 
NPM1 and HUR were identified as potential vPK substrates. To identify potential novel 
phosphorylation substrates of vPK, cell lysates from EV or vPK-expressing BJAB cells and 
HUVECs were collected by Dr. Ariana Bravo Cruz and submitted to the Proteomics Core at the 
University of North Carolina at Chapel Hill. The samples were analyzed by the Proteomics Core 
and a phosphoproteomic data set was generated, providing a list of human substrates that are 
likely to be phosphorylation targets of vPK, hereafter referred to as hits. Two hits from the high-
throughput phosphoproteomic data were of particular interest, NPM1 and HUR. The NPM1 gene 
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encodes a phosphoprotein called nucleophosmin, which affects chromatin remodeling, 
embryogenesis, and genome stability17. The disrupted regulation of NPM1 phosphorylation can 
result in a dysregulated cell cycle and cancer formation15.  The HUR gene encodes human 
antigen R, an RNA-binding protein that is known to increase the stability of mRNAs, including a 
number of cancer-related mRNAs18. The expression of HUR is also linked to tumorigenesis and 
the formation of multiple types of cancer16. Interestingly, NPM1 and HUR are both substrates of 
cyclin-dependent kinases (CDKs)15-16, a type of kinase that vPK is known to share functional 
similarities with14. The identification of NPM1, HUR, and several other proteins as high-
throughput phosphorylation substrates of vPK indicated that vPK is likely phosphorylating more 
cellular substrates than what is currently known.  
 
A new anti-vPK antibody is suitable for immunoblotting and immunoprecipitations. In order to 
characterize the novel phosphorylation targets of vPK, the conditions for a new anti-vPK 
antibody first had to be optimized. This antibody was necessary to confirm the expression of 
vPK in cells that were transfected (HEK-293T cells) or transduced (BJAB cells and HUVECs), 
but was recently acquired by the Damania Lab and had never before been used. Lysates from 
BJAB cells stably expressing EV or vPK were collected and immunoblotting was performed 
with the new anti-vPK antibody. Conditions for this antibody were optimized using another anti-
vPK antibody as a positive control. The positive control anti-vPK antibody had been readily used 
in the Damania Lab, although a limited quantity remained as it was a gift from another lab. With 
both antibodies, vPK was detected at approximately 50 kDa in vPK-expressing BJAB samples 
(Figure 1A); vPK is known to have a molecular weight (MW) of approximately 50 kDa. With 
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the new anti-vPK antibody, there was a non-specific band that appeared above the vPK band in 
both EV and vPK-expressing samples, above 50 kDa (Figure 1A). The 50 kDa vPK band is 
indicated by an arrow (Figure 1A). While expression of vPK was detectable using the new anti-
vPK antibody, the dilution required was higher than the dilution required of the gifted anti-vPK 
antibody (1:500 compared to 1:10,000). In addition to the 1:500 dilution factor, 10% milk was 
determined to be the best blocking condition for the new anti-vPK antibody because it showed 
less nonspecific binding compared to blots blocked with 5% milk.  
In addition to determining if the new anti-vPK antibody was able to detect vPK by 
immunoblotting, it was also imperative to determine if the new anti-vPK antibody could be used 
in immunoprecipitation assays to pull down vPK. Immunoprecipitations would be necessary as 
the project continued to test for the interactions between vPK and potential cellular substrates 
like NPM1 and HUR. We immunoprecipitated vPK from HEK-293T cell lysates with the new 
anti-vPK antibody then immunoblotted using an HRP-linked antibody that recognizes the v5 
epitope of vPK. We found that the new anti-vPK antibody is suitable for immunoprecipitation 
assays (Figure 2B). In sum, the new anti-vPK antibody was found to be suitable for both 
immunoblotting and coimmunoprecipitation assays.   
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Figure 1. A new anti-vPK antibody is suitable for immunoblotting and immunoprecipitations. (A) Immunoblot 
of lysates prepared from BJAB cells transduced to stably express EV or vPK. Blots were probed with the gifted anti-
vPK antibody as a positive control (I), the new anti-vPK antibody blocked in 5% milk (II), the new anti-vPK 
antibody blocked in 10% milk (III), or tubulin as a loading control (IV). Arrows in (II) and (III) indicate the vPK 
band. (B) Immunoblot of lysates prepared HEK-293T cells transfected with either EV or vPK under normal 
conditions for 24 hours. vPK was immunoprecipitated with the new anti-vPK antibody and blots were probed with 
an anti-v5 HRP-linked antibody to detect the presence of vPK.  
 
NPM1 phosphorylation appears unaffected by vPK. Phosphoproteomic data revealed that NPM1 
phosphorylation was likely to be increased by vPK, but this had not yet been validated by a 
biochemical assay. To confirm this result, immunoblotting was performed to test for differences 
in phospho-NPM1 levels between EV and vPK-expressing cells. HEK-293T cells were used 
because they are an easily transfectable cell line commonly used to study signaling pathways. 
Serum starvation was performed to synchronize cells to G0/G1 cell cycle phase and reduce basal 
cellular activity to potentially facilitate the visualization of the phosphorylation state of CDK 
substrates19. Conditions for the anti-phospho NPM1 and anti-NPM1 antibodies were optimized 
because this was the first time that these antibodies had been used in the Damania Lab. Blots 
were probed for phospho-NPM1 and total NPM1, which has an expected MW of 32 kDa. In an 
immunoblot, equal concentrations of NPM1 in EV and vPK-expressing cells should be seen if 
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vPK solely alters phosphorylation of NPM1 but has no effect on total protein levels. NPM1 
levels were consistent among EV and vPK-expressing cells under starvation and normal 
conditions (Figure 2A). In addition, no differences were observed in phospho-NPM1 levels 
between EV and vPK-expressing cells under starvation conditions (Figure 2A). However, under 
normal conditions, there seemed to be a decrease in phospho-NPM1 protein levels in vPK-
expressing cells compared to EV-expressing cells (Figure 2A). The same set of blots was also 
probed with the anti-vPK antibody to confirm vPK expression in the vPK-expressing cells 
(Figure 2A). 
While an increase of NPM1 phosphorylation was not detected in HEK-293T cells, this 
was not one of the cell lines that was submitted for phosphoproteomic analysis, bringing to our 
attention the possibility that vPK’s kinase activity on NPM1 could be cell type specific. To 
determine if we could detect differences in NPM1 phosphorylation in one of the cell lines that 
was used to generate the phosphoproteomic data, immunoblotting was performed with lysates 
from BJAB cells that were transduced to stably express EV or vPK. Blots were probed for 
phospho-NPM1, phospho-eIF4e, total eIF4e, tubulin, and vPK. eIF4e is a known substrate of 
vPK13 and is shown as a positive control to confirm that vPK kinase activity was functioning 
(Figure 2B). Blots were probed with the anti-vPK antibody to confirm vPK expression. Tubulin 
is shown as a loading control (Figure 2B). A slight increase in phospho-eIF4E levels was 
observed in vPK-expressing cells (Figure 2B). No differences were observed in phospho-NPM1 
levels between EV and vPK expressing cells under both starvation and normal conditions (Figure 
2B). 
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Given that no differences in phospho-NPM1 levels were observed in HEK-293T cells or 
BJAB cells, the specificity of the anti phospho-NPM1 antibody to detect only phosphorylated 
NPM1 and not total NPM1 was questioned. To confirm that the anti-phospho NPM1 antibody 
was specific to phospho-NPM1, HUVECs cells were treated with nocodazole. Nocodazole is 
known to enhance the phosphorylation of CDK substrates, including NPM1, by synchronizing 
cells to G2/M cell cycle phase, during which CDK1 is active20. Hence, nocodazole served here as 
a positive control. HUVECs were used because previous literature has shown a notable 
difference in the phosphorylation of HUR, another CDK1 substrate, in HUVECs treated with 
nocodazole18. In addition, HUVECs were included in the phosphoproteomics screen. To confirm 
that treatment with nocodazole was efficient to induce phosphorylation of CDK’s substrates, 
lysates from HUVECs were immunoblotted with an antibody that recognizes phosphoserine 
residues only on CDK substrates. Thus, one would expect to see an increase in levels of 
phosphorylated serine residues on CDK substrates in HUVECs treated with nocodazole. 
Immunoblotting indeed revealed an increase in the levels of phosphorylated serine residues on 
CDK substrates in both EV and vPK-expressing cells that were treated with nocodazole (Figure 
2C). 
Knowing that nocodazole effectively induced phosphorylation of CDK’s substrates, the 
next question addressed was if we could detect an increase in NPM1 phosphorylation in cells 
treated with nocodazole, which would confirm the specificity of the anti-phospho NPM1 
antibody to detect only phosphorylated NPM1 and not total NPM1. Immunoblotting revealed an 
increase of phospho-NPM1 in EV lysates treated with nocodazole in comparison to untreated EV 
lysates, suggesting that nocodazole successfully enhanced the phosphorylation of NPM1 (Figure 
2D) and that the anti-phospho NPM1 antibody is specific, given that total NPM1 levels were 
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consistent among the nocodazole-treated and untreated cells (Figure 2D). If NPM1 was 
phosphorylated by vPK, one would expect to see an increase in the concentration of phospho-
NPM1 in vPK-expressing HUVECs. However, phospho-NPM1 levels were consistent between 
the EV and vPK-expressing cells in both nocodazole treated and untreated cells (Figure 2D). 
Together, these results demonstrate no increase in phospho-NPM1 levels in vPK-expressing cells 
across three different cell types (Figure 2).  
 
Figure 2. NPM1 phosphorylation appears unaffected by vPK. (A) Immunoblot analysis of lysates prepared from 
HEK-293T cells transfected with EV or vPK under starvation conditions or normal conditions for 24 hours. Blots 
were probed with the indicated antibodies. (B) Immunoblot analysis of lysates prepared from BJABs cells 
transduced to stably express EV or vPK under starvation or normal conditions for 24 hours. Blots were probed with 
the indicated antibodies. The arrow indicates the vPK band in the last panel. (C) Immunoblot analysis of lysates 
prepared from HUVECs transduced to stably express EV or vPK and treated with (+) or without (-) nocodazole in 
5% FBS for 16 hours. Blots were probed with the indicated antibodies. Representative of two replicates.  (D) 
Immunoblot analysis of lysates prepared from HUVECs transduced to stably express EV or vPK and treated with 
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(+) nocodazole in 5% FBS for 16 hours or left untreated (-). Blots were probed with the indicated antibodies. 
Representative of two replicates.  
 
HUR does not appear to be interacting with vPK. Similarly to NPM1, it needed to be determined 
whether vPK was truly affecting the phosphorylation of HUR. If vPK does alter the 
phosphorylation of HUR, there should be a difference in levels of phosphorylated HUR protein 
between EV and vPK-expressing cells and no difference in total HUR protein levels. To confirm 
that there was no difference in total HUR protein levels among EV and vPK-expressing cells, 
immunoblotting was performed with HEK-293T cells. As before, HEK 293T cells were used 
because they are an easily transfectable cell line that is commonly used to study cell signaling 
pathways. Blots were probed for HUR, which has an expected MW of 36 kDa, using the same 
lysates from Figure 2. HUR was detected at a consistent level among EV and vPK-expressing 
cells (Figure 3A).  
 One indication that HUR is a vPK phosphorylation substrate is a detectable interaction 
between vPK and HUR. In order to test for any interaction between vPK and HUR, 
coimmunoprecipitations were performed by incubating BJAB lysates with an anti-HUR antibody 
to pull down HUR, followed by immunoblotting with an anti-vPK antibody. vPK was not 
observed in the immunoblots, suggesting no interaction between vPK and HUR (Figure 3B, 
upper panel). Lysates immunoblotted with anti-HUR antibody showed that HUR was 
successfully pulled down in all samples (Figure 3B, middle panel). Immunoprecipitation with an 
anti-IgG antibody was performed to ensure specificity of the antibodies utilized for pulldowns 
(Figure 3B, lower panel).  
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 Based on the results from the coimmunoprecipitations, it seemed that vPK and HUR were 
not interacting. However, vPK could have the function of phosphorylating HUR without 
interacting with it directly. Knowing that an increase in levels of phosphoserine CDK substrates 
could be visualized after treating cells with nocodazole (Figure 2C), the next question addressed 
was if we could detect a difference in HUR phosphorylation in nocodazole-treated cells and 
further enhanced phosphorylation in vPK-expressing cells. Immunoprecipitation assays were 
performed as there are no readily available antibodies to detect HUR phosphorylated at serine 
202, which was predicted by phosphoproteomics to be the residue phosphorylated by vPK. Total 
HUR protein was immunoprecipitated from EV and vPK-expressing HUVECs samples that were 
either treated with nocodazole for 16 hours or left untreated. To ensure that the bands being 
visualized were not the result of non-specific binding, immunoprecipitation assays were also 
performed with anti-mouse IgG antibody, which should not have been able to pull down the 
protein of interest. HUR was not detected at the expected MW of 36 kDa with the anti-
phosphoserine CDK substrate antibody (Figure 3C), even in samples treated with nocodazole. 
Blots probed for phosphoserine CDK substrates also showed a significant amount of nonspecific 
binding (Figure 3C). HUR was detected at 36 kDa in the samples immunoprecipitated with anti-
HUR antibody, followed by immunoblotting with anti-HUR antibody, meaning that HUR 
pulldown was successful (Figure 3C). The 36 kDa band is not present in the immunoprecipitated 
IgG sample, which is the expected result from the negative control and indicates that the 36 kDa 
band in the aforementioned blot was not a result of nonspecific binding (Figure 3C). Despite the 
successful pulldown of HUR, vPK was not detected in the coimmunoprecipitation assay with 
HUR (Figure 3C), as is also shown in Figure 3B. As a whole, these findings show no apparent 
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interaction between vPK and HUR and the inability to detect phosphorylated HUR, even in 
samples treated with nocodazole (Figure 3).  
 
Figure 3. HUR does not appear to be interacting with vPK. (A) Immunoblot analysis of lysates prepared from 
HEK-293T cells transfected with either EV or vPK under starvation conditions or normal conditions for 24 hours. 
Blots were probed with the indicated antibodies. (B) Immunoblot analysis of lysates prepared from BJABs cells 
transduced to stably express EV or vPK under normal conditions for 24 hours. Immunoprecipitations were 
performed as indicated. Blots were probed with the indicated antibodies. (C) Immunoblot analysis of lysates 
prepared from HUVECs transduced to stably express EV or vPK and treated with (+) nocodazole in 5% FBS for 16 
hours or left untreated (-). Immunoprecipitations were performed as indicated. Blots were probed with the indicated 
antibodies.  
 
Discussion  
Immunoblotting revealed that the overall protein levels of two cellular substrates of 
interest, NPM1 and HUR, were not changed in the presence or absence of vPK (Figure 2-3). It 
was expected that vPK would not affect the total concentrations of these proteins if vPK 
functioned strictly to phosphorylate these substrates, which was confirmed. However, NPM1 
phosphorylation was not increased in vPK-expressing cells (Figure 2). Coimmunoprecipitations 
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indicated that vPK may not be interacting with HUR (Figure 3), despite phosphoproteomic data 
suggesting that HUR is a likely phosphorylation target of vPK.  
From our results, we can infer that NPM1 phosphorylation is not affected by vPK. It can 
also be inferred that vPK and HUR do not interact, however, this experiment should be repeated 
with better controls. Whether or not vPK phosphorylates HUR remains elusive. More 
immunoprecipitation experiments will be performed to determine if vPK affects the 
phosphorylation status of HUR. If it is determined that vPK is able to phosphorylate HUR, 
further research will be done to determine if vPK directly phosphorylates HUR or an upstream 
regulator. While it seems unlikely that NPM1 is a substrate of vPK, other high-throughput 
cellular substrates from the phosphoproteomic data could still be investigated. One potential 
substrate of vPK that we are starting to explore is Ras-related protein 1 (Rab1).    
One caveat of immunoprecipitations is that the binding sites for either the vPK or HUR 
antibodies might be masked by an interaction between vPK and HUR. To address this, we can 
instead perform coimmunoprecipitations with antibodies against tagged vPK and HUR proteins. 
Another caveat of immunoprecipitations is the amount of nonspecific binding, which can be seen 
especially in Figure 3D. This can be addressed in the future by adding a “pre-clearing” step to 
the immunoprecipitation protocol, which would significantly reduce the amount of nonspecific 
binding.  
 It was unexpected that we would experience difficulty detecting an increase in phospho-
eIF4E levels in vPK-expressing cells (Figure 2B), which disagrees with literature that shows 
eIF4E as a substrate of vPK13. Immunoblotting was also performed for phospho-S6, another 
known substrate of vPK13, but an increase in S6 phosphorylation could not be detected in vPK-
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expressing cells (not shown). A possible interpretation of these findings is that the 
immunoblotting technique still needs to be optimized for better detection of phosphorylated 
vPK's substrates. An alternative to immunoblotting could be to test for HUR phosphorylation in 
vivo using radiolabeled ATP20. 
 Overall, the identification of new phosphorylation substrates of vPK, such as NPM1 and 
HUR, has the potential for the development of new treatments for KSHV-related cancers by 
targeting vPK kinase activity. KSHV is able to establish cancer in its host by manipulating the 
cellular environment and vPK has been shown to aid in this process by altering protein 
phosphorylation, which can activate protein synthesis, induce angiogenesis, and promote the 
multiplication of virally infected cells18. 
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